Core Viewpoint - Beihai Kangcheng Pharmaceutical Co., Ltd. has announced a share subscription agreement with Qingdao Baiyang Pharmaceutical Co., Ltd., marking a significant strategic collaboration in the rare disease sector in China [1] Group 1: Share Subscription Agreement - Baiyang Pharmaceutical will subscribe for shares valued at approximately 100 million HKD at a price of 1.34 HKD per share [1] - Beihai Kangcheng will issue 75 million new shares, which will represent about 17.65% of the existing issued share capital and 14.99% of the enlarged share capital post-transaction [1] Group 2: Strategic Collaboration - The companies have signed an exclusive commercialization service agreement, allowing Baiyang Pharmaceutical's subsidiary to promote specific products of Beihai Kangcheng in mainland China and Hong Kong and Macau [1] - The strategic equity financing aims to optimize Beihai Kangcheng's commercialization business model and enhance its operational capabilities, accelerating market penetration of its already listed products [1]
百洋医药拟战略认购罕见病龙头北海康成0.75亿股